Dr. Reddy’s Laboratories has launched Methylprednisolone Sodium Succinate for Injection, USP, the generic equivalent of SOLU-MEDROL (methylprednisolone sodium succinate for injection, USP) in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA).
The SOLU-MEDROL brand and generic had U.S. sales of around $144 million MAT for the most recent twelve months ending in February 2022 according to IQVIA Health.
Dr. Reddy’s Methylprednisolone Sodium Succinate for Injection, USP, is supplied in 40 mg/vial, 125 mg/vial single-dose vials each carton containing 25 vials; 500 mg and 1 gm multi-dose vial each carton containing 1 vial.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: